Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis : results from a UK national register

Macfarlane, Gary JMacDonald, Ross I RPathan, EjazSiebert, StefanGaffney, KarlChoy, ErnestPackham, JonMartin, Kathryn RHaywood, KirstieSengupta, RajAtzeni, FabiolaJones, Gareth T2018-07-242018-07-242018-11-01Macfarlane, G J, MacDonald, R I R, Pathan, E, Siebert, S, Gaffney, K, Choy, E, Packham, J, Martin, K R, Haywood, K, Sengupta, R, Atzeni, F & Jones, G T 2018, 'Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis : results from a UK national register', Rheumatology, vol. 57, no. 11, pp. 1982-1990. https://doi.org/10.1093/rheumatology/key2061462-0324RIS: urn:031119A450CAB072AAE972126922D4D4RIS: urn:031119A450CAB072AAE972126922D4D4ORCID: /0000-0003-2322-3314/work/72631710ORCID: /0000-0003-0016-7591/work/83703966ORCID: /0000-0003-4539-7147/work/153002098http://hdl.handle.net/2164/10790Funding: This work was supported by Arthritis Research UK (grant 21378) conducted as part of the Fibromyalgia Optimal Management in Axial Spondyloarthritis study.8218075engaxial spondyloarthritisbiologic therapycohort studyco-morbiditydisease activitydisease registerepidemiologyfibromyalgiaoutcomeresponseR MedicineArthritis Research UK (ARUK)21378RInfluence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis : results from a UK national registerJournal article10.1093/rheumatology/key2065711